Citius Pharmaceuticals Raises $5 Million Through Direct Stock Offering at $0.985 Per Share

Key Takeaways

• Citius Pharmaceuticals raised $5 million through direct offering of 5.08 million shares at $0.985 per share
• Funds will support development and commercialization of first-in-class critical care pharmaceutical products
• Offering priced at-the-market under Nasdaq rules, providing immediate capital for ongoing operations

---

Citius Pharmaceuticals Secures $5 Million in Capital

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) announced April 24, 2026, that it has completed a registered direct offering raising $5 million to advance its critical care drug development pipeline. The Cranford, New Jersey-based biopharmaceutical company sold 5,076,143 shares of common stock at $0.985 per share.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Funding Strategy and Market Positioning

The offering was structured as a registered direct placement, allowing Citius to raise capital efficiently while maintaining compliance with Nasdaq listing requirements. Investors had the option to purchase pre-funded warrants in lieu of common stock, providing flexibility in the transaction structure.

This capital raise comes as Citius continues developing first-in-class treatments for critical care applications. The company focuses on addressing unmet medical needs in hospital and intensive care settings, where treatment options remain limited.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Impact on Operations and Development

The $5 million injection provides Citius with working capital to advance its pharmaceutical development programs and support commercialization efforts. For a specialized biopharmaceutical company, this funding level represents significant runway for clinical trials and regulatory activities.

The at-the-market pricing under Nasdaq rules ensures the offering meets exchange requirements while providing fair market value to both existing shareholders and new investors. This approach helps minimize dilution concerns while securing necessary operating capital.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Market Context

Critical care pharmaceuticals represent a high-need therapeutic area with significant commercial potential. Citius’s focus on first-in-class products positions the company to capture market share in underserved segments of hospital medicine.

The successful completion of this offering demonstrates investor confidence in Citius’s development strategy and management team’s ability to execute on clinical and commercial milestones.

---

Frequently Asked Questions

What will Citius use the $5 million for?

The funds will support development and commercialization of Citius’s first-in-class critical care pharmaceutical products, including clinical trials and regulatory activities.

How does this offering affect existing shareholders?

The offering adds 5.08 million shares, creating dilution for existing shareholders, but provides necessary capital for advancing the company’s drug development programs.

What makes Citius’s critical care products different?

Citius focuses on first-in-class treatments for critical care settings, targeting unmet medical needs in hospitals and intensive care units where current treatment options are limited.

Related coverage

• Eli Lilly raises 2026 revenue guidance on Mounjaro demand